Lefort, M., Sharmin, S., Maillart, E., Zephir, H., Labauge, P., Defer, G., Lebrun-Frenay, C., Moreau, T., Berger, E., Clavelou, P., Pelletier, J., Stankoff, B., Andersen, J. B., Gout, O., Lechner-Scott, J., .,, .,, .,, .,, .,, .,, .,, .,, Vukusic, S., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Casey, R., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Debouverie, M., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Edan, G., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Ciron, J., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Ruet, A., .,, .,, .,, .,, .,, .,, .,, .,, De Sèze, J.. BioMed Central; 2022. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.